Eyebiotech Limited
- Address
- 120 Moorgate
Sponsor Overview
Specializations
Retinal Disease Research
Eyebiotech Limited focuses on clinical research in diabetic macular edema, with an emphasis on treatment approaches for vision loss linked to retinal vascular disease and macular swelling.
- Diabetic macular edema
- Retinal pathology
- Macular edema
The sponsor's trial activity is centred on ophthalmic outcomes relevant to central vision and retinal health.
Ophthalmology and Vision Care
The sponsor supports studies in ophthalmology that evaluate therapies intended to preserve or improve best-corrected visual acuity in patients with diabetic eye disease.
- Best-corrected visual acuity
- Visual function
- Diabetic eye disease
This area reflects a clear interest in clinical endpoints tied to sight-threatening retinal conditions.
Anti-VEGF Therapeutics
Eyebiotech Limited is engaged in research on anti-vascular endothelial growth factor treatment strategies, including intravitreal approaches for retinal disorders associated with fluid accumulation and impaired vision.
- Anti-VEGF therapy
- Intravitreal treatment
- Vascular endothelial growth factor inhibition
The sponsor's therapeutic interest is directed toward agents used in chronic retinal disease management.
Clinical Ophthalmic Outcomes
Its research activity places attention on measurable eye-care outcomes such as ETDRS visual acuity assessment and changes in central retinal function over time.
- ETDRS chart assessment
- Visual acuity endpoints
- Retinal function
These interests align with clinical evaluation of therapies for diseases affecting the macula and central vision.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Intravitreal EYE103 Versus Ranibizumab in Diabetic Macular Edema: A Randomized, Double-Masked, Phase 2/3 Study |  Austria Croatia Czechia France Germany Hungary Italy Latvia Poland Portugal Slovakia Spain | Not Recruiting |
| Evaluation of Efficacy and Safety of Intravitreal EYE103 Versus Ranibizumab in Diabetic Macular Edema: A Randomized, Double-Masked, Multi-Center Study | Austria Croatia Czechia France Germany Hungary Italy Latvia Poland Portugal Slovakia Spain | Not Recruiting |
| Randomized, Double-Masked, Multicenter Phase 2/3 Trial of Intravitreal MK-8748 Versus Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration | Austria Croatia Czechia Denmark France Hungary Italy Portugal Slovakia Spain | Recruiting |
| Randomized, Double‑Masked, Multicenter Phase 2/3 Trial of Intravitreal MK‑8748 versus Aflibercept in Neovascular Age‑Related Macular Degeneration |  Estonia Germany Latvia Poland Spain | Recruiting |
Data & Insights
This sponsor works with 4 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 97 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases4 trials138 other sponsors
Partnered Research Centres
97 centres- Address
- Azinhaga De Santa Comba, 3000-548 Coimbra
- Address
- Via Giovanni Battista Grassi 74, 20157 Milan
- Address
- Chlumcanskeho 497/5, Liben, 180 00 Prague
- Address
- Hohenzollernring 74, Herz-Jesu, 48145 Munster
- Address
- Ostrovskeho 253/3, Smichov, 150 00 Prague
- Address
- Via Cherasco 15, 10126 Turin
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Eyebiotech Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.